CDKN2A and aneurysmal bone cyst: Molecular characteristics like ABC cell-of-origin, MCD phenotype, TP53 mutation, double hit, or CDKN2A deletion (del9p) combined with clinical parameters could help to stratify patients and rationalize the use of CNS prophylaxis.